Cargando…

A Chemical Analog of Curcumin as an Improved Inhibitor of Amyloid Abeta Oligomerization

Amyloid-like plaques are characteristic lesions defining the neuropathology of Alzheimer's disease (AD). The size and density of these plaques are closely associated with cognitive decline. To combat this disease, the few therapies that are available rely on drugs that increase neurotransmissio...

Descripción completa

Detalles Bibliográficos
Autores principales: Orlando, Robert A., Gonzales, Amanda M., Royer, Robert E., Deck, Lorraine M., Vander Jagt, David L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3307704/
https://www.ncbi.nlm.nih.gov/pubmed/22442659
http://dx.doi.org/10.1371/journal.pone.0031869
_version_ 1782227348475609088
author Orlando, Robert A.
Gonzales, Amanda M.
Royer, Robert E.
Deck, Lorraine M.
Vander Jagt, David L.
author_facet Orlando, Robert A.
Gonzales, Amanda M.
Royer, Robert E.
Deck, Lorraine M.
Vander Jagt, David L.
author_sort Orlando, Robert A.
collection PubMed
description Amyloid-like plaques are characteristic lesions defining the neuropathology of Alzheimer's disease (AD). The size and density of these plaques are closely associated with cognitive decline. To combat this disease, the few therapies that are available rely on drugs that increase neurotransmission; however, this approach has had limited success as it has simply slowed an imminent decline and failed to target the root cause of AD. Amyloid-like deposits result from aggregation of the Aβ peptide, and thus, reducing amyloid burden by preventing Aβ aggregation represents an attractive approach to improve the therapeutic arsenal for AD. Recent studies have shown that the natural product curcumin is capable of crossing the blood-brain barrier in the CNS in sufficient quantities so as to reduce amyloid plaque burden. Based upon this bioactivity, we hypothesized that curcumin presents molecular features that make it an excellent lead compound for the development of more effective inhibitors of Aβ aggregation. To explore this hypothesis, we screened a library of curcumin analogs and identified structural features that contribute to the anti-oligomerization activity of curcumin and its analogs. First, at least one enone group in the spacer between aryl rings is necessary for measureable anti-Aβ aggregation activity. Second, an unsaturated carbon spacer between aryl rings is essential for inhibitory activity, as none of the saturated carbon spacers showed any margin of improvement over that of native curcumin. Third, methoxyl and hydroxyl substitutions in the meta- and para-positions on the aryl rings appear necessary for some measure of improved inhibitory activity. The best lead inhibitors have either their meta- and para-substituted methoxyl and hydroxyl groups reversed from that of curcumin or methoxyl or hydroxyl groups placed in both positions. The simple substitution of the para-hydroxy group on curcumin with a methoxy substitution improved inhibitor function by 6-7-fold over that measured for curcumin.
format Online
Article
Text
id pubmed-3307704
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-33077042012-03-22 A Chemical Analog of Curcumin as an Improved Inhibitor of Amyloid Abeta Oligomerization Orlando, Robert A. Gonzales, Amanda M. Royer, Robert E. Deck, Lorraine M. Vander Jagt, David L. PLoS One Research Article Amyloid-like plaques are characteristic lesions defining the neuropathology of Alzheimer's disease (AD). The size and density of these plaques are closely associated with cognitive decline. To combat this disease, the few therapies that are available rely on drugs that increase neurotransmission; however, this approach has had limited success as it has simply slowed an imminent decline and failed to target the root cause of AD. Amyloid-like deposits result from aggregation of the Aβ peptide, and thus, reducing amyloid burden by preventing Aβ aggregation represents an attractive approach to improve the therapeutic arsenal for AD. Recent studies have shown that the natural product curcumin is capable of crossing the blood-brain barrier in the CNS in sufficient quantities so as to reduce amyloid plaque burden. Based upon this bioactivity, we hypothesized that curcumin presents molecular features that make it an excellent lead compound for the development of more effective inhibitors of Aβ aggregation. To explore this hypothesis, we screened a library of curcumin analogs and identified structural features that contribute to the anti-oligomerization activity of curcumin and its analogs. First, at least one enone group in the spacer between aryl rings is necessary for measureable anti-Aβ aggregation activity. Second, an unsaturated carbon spacer between aryl rings is essential for inhibitory activity, as none of the saturated carbon spacers showed any margin of improvement over that of native curcumin. Third, methoxyl and hydroxyl substitutions in the meta- and para-positions on the aryl rings appear necessary for some measure of improved inhibitory activity. The best lead inhibitors have either their meta- and para-substituted methoxyl and hydroxyl groups reversed from that of curcumin or methoxyl or hydroxyl groups placed in both positions. The simple substitution of the para-hydroxy group on curcumin with a methoxy substitution improved inhibitor function by 6-7-fold over that measured for curcumin. Public Library of Science 2012-03-19 /pmc/articles/PMC3307704/ /pubmed/22442659 http://dx.doi.org/10.1371/journal.pone.0031869 Text en Orlando et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Orlando, Robert A.
Gonzales, Amanda M.
Royer, Robert E.
Deck, Lorraine M.
Vander Jagt, David L.
A Chemical Analog of Curcumin as an Improved Inhibitor of Amyloid Abeta Oligomerization
title A Chemical Analog of Curcumin as an Improved Inhibitor of Amyloid Abeta Oligomerization
title_full A Chemical Analog of Curcumin as an Improved Inhibitor of Amyloid Abeta Oligomerization
title_fullStr A Chemical Analog of Curcumin as an Improved Inhibitor of Amyloid Abeta Oligomerization
title_full_unstemmed A Chemical Analog of Curcumin as an Improved Inhibitor of Amyloid Abeta Oligomerization
title_short A Chemical Analog of Curcumin as an Improved Inhibitor of Amyloid Abeta Oligomerization
title_sort chemical analog of curcumin as an improved inhibitor of amyloid abeta oligomerization
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3307704/
https://www.ncbi.nlm.nih.gov/pubmed/22442659
http://dx.doi.org/10.1371/journal.pone.0031869
work_keys_str_mv AT orlandoroberta achemicalanalogofcurcuminasanimprovedinhibitorofamyloidabetaoligomerization
AT gonzalesamandam achemicalanalogofcurcuminasanimprovedinhibitorofamyloidabetaoligomerization
AT royerroberte achemicalanalogofcurcuminasanimprovedinhibitorofamyloidabetaoligomerization
AT decklorrainem achemicalanalogofcurcuminasanimprovedinhibitorofamyloidabetaoligomerization
AT vanderjagtdavidl achemicalanalogofcurcuminasanimprovedinhibitorofamyloidabetaoligomerization
AT orlandoroberta chemicalanalogofcurcuminasanimprovedinhibitorofamyloidabetaoligomerization
AT gonzalesamandam chemicalanalogofcurcuminasanimprovedinhibitorofamyloidabetaoligomerization
AT royerroberte chemicalanalogofcurcuminasanimprovedinhibitorofamyloidabetaoligomerization
AT decklorrainem chemicalanalogofcurcuminasanimprovedinhibitorofamyloidabetaoligomerization
AT vanderjagtdavidl chemicalanalogofcurcuminasanimprovedinhibitorofamyloidabetaoligomerization